Eli Lilly & Co

Discover how Eli Lilly’s $1 trillion valuation surge is driven by GLP‑1 drugs like Mounjaro and Zepbound, Medicare pricing moves, and strategic R&D pivots for future growth.

Explore how Eli Lilly’s $74 % price cut and eloralintide’s Phase 2 success are reshaping the obesity‑drug market, boosting shares and investor confidence.

Discover how Eli Lilly’s record Q3 earnings and a Medicare price‑cut deal for weight‑loss drugs are propelling the company’s stock and reshaping the U.S. obesity‑drug market.

Eli Lilly & Co.’s stock price declined sharply after a study revealed disappointing results for its experimental weight-loss pill, Orforglipron.

Eli Lilly & Co. reported a first-quarter earnings miss, sending its stock plummeting, amidst intense competition and strategic challenges in the weight-loss drug market.